Business
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025DTP offering to expand to other appropriate products; exploring additional direct-to-employer model to increase access and affordability for cash-paying patients in the US Basel, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying pati
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":287,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jVHT.jc1r.9_PBg7JQVa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308","width":287,"height":55}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"DTP offering to expand to other appropriate products; exploring additional direct-to-employer model to increase access and affordability for cash-paying patients in the US","length":171,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":310,"olType":false},{"type":"text","content":"Basel, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients prescribed Cosentyx® (secukinumab) the option to purchase it at a 55% discount off the list price. Cosentyx, Novartis top selling product in the US, is a biologic that is FDA-approved for the treatment of multiple immune-mediated inflammatory diseases, including psoriasis, hidradenitis suppurativa and psoriatic arthritis. It has been studied clinically for more than 17 years and has been used to treat more than 1.8 million patients globally since its launch in 2015.","length":664,"tagName":"p"},{"type":"text","content":"“Breakthrough innovation is what drives us at Novartis, in scientific research, medicine development, and in the ways in which we deliver our innovation to patients. In the US, we have long recognized that we need new ways to reach patients more directly by removing barriers in the system,” said Victor Bultó, President, US for Novartis. “The launch of this new platform is a first step as we continue to work toward solutions to provide our net prices more directly to patients and make the healthcare system work better for Americans.”","length":538,"tagName":"p"},{"type":"text","content":...